|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Quek ML, Stein JP, Clark PE, Daneshmand S,
Miranda G, Cai J, Groshen S, Lieskovsky G, Quinn DI, Raghavan D, et
al: Natural history of surgically treated bladder carcinoma with
extravesical tumor extension. Cancer. 98:955–961. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Babjuk M, Oosterlinck W, Sylvester R,
Kaasinen E, Böhle A and Palou-Redorta J: European Association of
Urology (EAU): EAU guidelines on non-muscle-invasive urothelial
carcinoma of the bladder. Eur Urol. 54:303–314. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Visone R and Croce CM: MiRNAs and cancer.
Am J Pathol. 174:1131–1138. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
GriffithsJones S, Saini HK, van Dongen S
and Enright AJ: miRBase: Tools for microRNA genomics. Nucleic Acids
Res. 36:D154–D158. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Neely LA, RiegerChrist KM, Neto BS,
Eroshkin A, Garver J, Patel S, Phung NA, McLaughlin S, Libertino
JA, Whitney D, et al: A microRNA expression ratio defining the
invasive phenotype in bladder tumors. Urol Oncol. 28:39–48. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wszolek MF, RiegerChrist KM, Kenney PA,
Gould JJ, Silva Neto B, Lavoie AK, Logvinenko T, Libertino JA and
Summerhayes IC: A MicroRNA expression profile defining the invasive
bladder tumor phenotype. Urol Oncol. 29:794–801. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jajoo S, Mukherjea D, Kaur T, Sheehan KE,
Sheth S, Borse V, Rybak LP and Ramkumar V: Essential role of NADPH
oxidase-dependent reactive oxygen species generation in regulating
microRNA-21 expression and function in prostate cancer. Antioxid
Redox Signal. 19:1863–1876. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang HH, Qi F, Zu XB, Cao YH, Miao JG, Xu
L and Qi L: A proteomic study of potential VEGF-C-associated
proteins in bladder cancer T24 cells. Med Sci Monit.
18:BR441–BR449. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang H, Qi F, Cao Y, Zu X, Chen M, Li Z
and Qi L: 5-Aza-2′-deoxycytidine enhances maspin expression and
inhibits proliferation, migration and invasion of the bladder
cancer T24 cell line. Cancer Biother Radiopharm. 28:343–350. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Babjuk M, Burger M, Zigeuner R, Shariat
SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A,
Palou Redorta J and Rouprêt M: European Association of Urology: EAU
guidelines on non-muscle-invasive urothelial carcinoma of the
bladder: Update 2013. Eur Urol. 64:639–653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fu X, Han Y, Wu Y, Zhu X, Lu X, Mao F,
Wang X, He X and Zhao Y and Zhao Y: Prognostic role of microRNA-21
in various carcinomas: A systematic review and meta-analysis. Eur J
Clin Invest. 41:1245–1253. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu G, Zhang Y, Wei J, Jia W, Ge Z, Zhang Z
and Liu X: MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell
proliferation through repression of mitogen-activated protein
kinase-kinase 3. BMC Cancer. 13:4692013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kawakita A, Yanamoto S, Yamada S, Naruse
T, Takahashi H, Kawasaki G and Umeda M: MicroRNA-21 promotes oral
cancer invasion via the Wnt/β-catenin pathway by targeting DKK2.
Pathol Oncol Res. 20:253–261. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Guancial EA, Bellmunt J, Yeh S, Rosenberg
JE and Berman DM: The evolving understanding of microRNA in bladder
cancer. Urol Oncol. 32:e31–e40. 2013.PubMed/NCBI
|
|
18
|
Meng F, Henson R, WehbeJanek H, Ghoshal K,
Jacob ST and Patel T: MicroRNA-21 regulates expression of the PTEN
tumor suppressor gene in human hepatocellular cancer.
Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhu S, Si ML, Wu H and Mo YY: MicroRNA-21
targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol
Chem. 282:14328–14336. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhu S, Wu H, Wu F, Nie D, Sheng S and Mo
YY: MicroRNA-21 targets tumor suppressor genes in invasion and
metastasis. Cell Res. 18:350–359. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bodenstine TM, Seftor RE, KhalkhaliEllis
Z, Seftor EA, Pemberton PA and Hendrix MJ: Maspin: Molecular
mechanisms and therapeutic implications. Cancer Metastasis Rev.
31:529–551. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
McGowen R, Biliran H Jr, Sager R and Sheng
S: The surface of prostate carcinoma DU145 cells mediates the
inhibition of urokinase-type plasminogen activator by maspin.
Cancer Res. 60:4771–4778. 2000.PubMed/NCBI
|
|
23
|
Zheng H, Tsuneyama K, Cheng C, Takahashi
H, Cui Z, Murai Y, Nomoto K and Takano Y: Maspin expression was
involved in colorectal adenoma-adenocarcinoma sequence and liver
metastasis of tumors. Anticancer Res. 27:259–265. 2007.PubMed/NCBI
|
|
24
|
Ali S, Almhanna K, Chen W, Philip PA and
Sarkar FH: Differentially expressed miRNAs in the plasma may
provide a molecular signature for aggressive pancreatic cancer. Am
J Transl Res. 3:28–47. 2010.PubMed/NCBI
|
|
25
|
Torres A, Torres K, Paszkowski T, Radej S,
Staśkiewicz GJ, Ceccaroni M, Pesci A and Maciejewski R: Highly
increased maspin expression corresponds with up-regulation of
miR-21 in endometrial cancer: A preliminary report. Int J Gynecol
Cancer. 21:8–14. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Su JL, Yen CJ, Chen PS, Chuang SE, Hong
CC, Kuo IH, Chen HY, Hung MC and Kuo ML: The role of the
VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer. 96:541–545.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
DeMei M, XiangXin L, YongPing X, YongXia
Y, YunHai Y and Lin Z: Vascular endothelial growth factor C
expression is closely correlated with lymph node recurrence and
poor prognosis in patients with early stage cervical cancer. J Int
Med Res. 41:1541–1549. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang Y, Meng X, Zeng H, Guan Y, Zhang Q,
Guo S, Liu X and Guo Q: Serum vascular endothelial growth factor-C
levels: A possible diagnostic marker for lymph node metastasis in
patients with primary non-small cell lung cancer. Oncol Lett.
6:545–549. 2013.PubMed/NCBI
|
